Latest stories on VSTM
Verastem to unveil new clinical data on VS-7375
The Fly63 · neutralproduct/pr
Verastem Oncology to Participate in Upcoming September Investor Conferences
StockTitan56 · neutralgeneral
Verastem: A Rare-Disease Launch Is Financing A KRAS G12D Platform
Seeking Alpha63 · neutralproduct/pr
Verastem (VSTM) Q2 2026 Earnings Call Transcript
The Motley Fool67 · bullishearnings
Verastem Price Target Lowered To 13 From 14 At Mizuho Thefly News 2
The Fly38 · neutralanalyst
Mizuho lowers Verastem stock price target on valuation to $13
Investing.com Analyst Ratings34 · bearishanalyst
Verastem Price Target Lowered To 13 From 14 At Mizuho
The Fly34 · bearishanalyst
Verastem Q2 Earnings Call Highlights
Yahoo Top59 · neutralearnings
Verastem outlines October VS-7375 response-rate update while targeting LGSOC self-sustainability by end of 2026
Seeking Alpha63 · neutralproduct/pr
Verastem, Inc. (VSTM) Q2 2026 Earnings Call Transcript
Seeking Alpha50 · neutralearnings
Verastem price target lowered to $12 from $14 at Guggenheim
The Fly38 · neutralanalyst
Verastem, Inc. 2026 Q2 - Results - Earnings Call Presentation
Seeking Alpha50 · neutralearnings
Verastem, Inc. (VSTM) files 8-K
SEC 8-K50 · neutralgeneral
Verastem Reports Q2 Adjusted Eps 31c Consensus 44c
The Fly34 · bearishearnings
Verastem Oncology Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates
StockTitan54 · neutralearnings
Verastem Oncology to Report Second Quarter 2026 Financial Results on August 6, 2026
StockTitan50 · neutralgeneral
RBC Capital Reaffirms Outperform Rating For Verastem (VSTM)
Yahoo Finance61 · neutralanalyst
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | VSTM Stock News
StockTitan50 · neutralgeneral
Verastem’s RAMP 204 Trial Completion Signals New Momentum in KRAS G12C Lung Cancer
TipRanks63 · neutralproduct/pr
Verastem, Inc. (VSTM) Discusses Preliminary TARGET-D 101 Data for VS-7375 in KRAS G12D Mutated Cancers - Slideshow
Seeking Alpha55 · neutralproduct/pr
Verastem, Inc. (VSTM) Discusses Preliminary TARGET-D 101 Data for VS-7375 in KRAS G12D Mutated Cancers Transcript
Seeking Alpha56 · neutralproduct/pr
Verastem Advances VS-7375 with Promising Early Trial Data
TipRanks67 · bullishproduct/pr